Articles, Case Studies and Resources | Acumetis

The Greek Innovation Fund: a new framework for access to innovative therapies

Learn how Greece's Innovation Fund is advancing earlier access to innovative therapies through a new market access framework.

Direct-to-employer drug models: From niche access model to channel strategy

Discover the market forces driving direct-to-employer adoption and what makes therapies strong candidates for direct commercialization.

Why Most Favored Nation pricing is becoming a political imperative

Explore how Most Favored Nation (MFN) pricing could impact pharmaceutical pricing, reimbursement, market access, and evidence strategies for life sciences organizations.

How to navigate loss of exclusivity with a strategic commercial playbook

Download the playbook to learn how leading organizations prepare for and manage loss of exclusivity.

Developing a direct-to-employer strategy for gross-to-net optimization

Learn how Acumetis evaluated a direct-to-employer strategy, identify partnership opportunities, and develop a roadmap to support GTN improvement and future commercialization decisions.

Meet Acumetis at World EPA 2027!

Meet the Acumetis GVA team at World EPA 2027 in Amsterdam as a Platinum Sponsor, exploring evidence, pricing, reimbursement, and access strategies across global markets.

Meet Acumetis at ISPOR EU 2026!

Meet Acumetis at ISPOR EU 2026 in Vienna. From PICO development and Joint Clinical Assessments to HEOR and market access, discover how Acumetis helps organizations turn evidence into value.

FRM Proactivity: Reduce enrollment errors and accelerate turnaround time

Discover how proactive FRM engagement, data-driven case prioritization, and cross-functional tracking improved efficiency, reduced enrollment errors, and accelerated patient access.

Transforming field reimbursement managers: reactive to proactive strategic enablement

Learn how proactive, data-driven solutions help reduce access barriers, improve account planning, and accelerate patient onboarding.